Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All director nominees elected through 2029, preserving board continuity.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All director nominees elected through 2029, preserving board continuity
- Executive compensation approved with 70,478,374 votes for, supporting current pay structure
- Grant Thornton Zhitong auditor appointment ratified for 2026 with 72,487,596 votes for
- Series B preferred conversion approved under Nasdaq Rule 5635(a), enabling potential common-stock issuance and dilution
- 96,994,001 shares eligible to vote; 1,985,197 broker non-votes on contested proposals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.